Retinitis Pigmentosa Panel: Sequencing and CNV Analysis

**Test Code:** MM233  
**Turnaround time:** 6 weeks  
**CPT Codes:** 81404 x1, 81406 x1, 81408 x1

### Condition Description

Retinitis pigmentosa (RP) is a heterogeneous group of inherited diseases that commonly results in a progressive retinal degeneration. Over 90 forms of RP have been identified. RP can be syndromic or nonsyndromic and can be inherited in an autosomal dominant, autosomal recessive, or X-linked manner. RP is characterized by progressive visual field loss, night blindness, and abnormal or nonrecordable electroretinogram (ERG). Fundus changes include pigment deposition in the retina along the blood vessels with optic nerve pallor and arteriolar narrowing in early stages advancing to characteristic "bone spicule" pigmentary pattern in later stages. Please note that RPGR orf15 analysis is not included in this test.


**References:**
- OMIM
- GeneReviews

### Genes

- *ABCA4, AIP1, BBS1, BEST1, C1QTNF5, C8orf37, C4A, CERKL, CHM, CLN3, CLRN1, CNGA1, CNGB1, CRB1, CRX, CYP4V2, DHDDS, EYS, FAM161A, FLVCR1, FSCN2, GUC1A1, GUCY2D, IDH3B, IMPDH1, IMPG2, KAL1, LRAT, MAK, MERTK, NR2E3, NRC1, PCARE, PDE6A, PDE6B, PDE6G, PRCD, PROM1, PRPF3, PRPF31, PRPF6, PRPF8, PRPH2, RBP1, RBP3, RBP4, RDH12, RGR, RHOD, RBP1, ROM1, RP1, RP2, RP3, RPE65, RGR, RPRP1, SAG, SEMA4A, SNRNP200, SPATA7, TOPORS, TTC8, TULP1, USH2A, ZNF513*

### Indications

- Confirmation of a clinical diagnosis of retinitis pigmentosa.
- Carrier testing in adults with a family history of retinitis pigmentosa.

### Methodology

**Next Generation Sequencing:** In-solution hybridization of all coding exons is performed on the patient's genomic DNA. Although some deep intronic regions may also be analyzed, this assay is not meant to interrogate most promoter regions, deep intronic regions, or other regulatory elements, and does not detect single or multi-exon deletions or duplications. Direct sequencing of the captured regions is performed using next generation sequencing. The patient's gene sequences are then compared to a standard reference sequence. Potentially causative variants and areas of low coverage are Sanger-sequenced. Sequence variations are classified as pathogenic, likely pathogenic, benign, likely benign, or variants of unknown significance. Variants of unknown significance may require further studies of the patient and/or family members.

**Copy Number Analysis:** Comparative analysis of the NGS read depth (coverage) of the targeted regions of genes on this panel was performed to detect copy number variants (CNV). The accuracy of the detected variants is highly dependent on the size of the event, the sequence context and the coverage obtained for the targeted region. Due to these variables and limitations a minimum validated CNV size cannot be determined; however, single exon deletions and duplications are expected to be below the detection limit of this analysis.

### Detection

**Clinical Sensitivity:** Unknown. Pathogenic variants in the promoter region, some pathogenic variants in the introns and other regulatory element pathogenic variants cannot be detected by this analysis. Results of molecular analysis should be interpreted in the context of the patient’s clinical and/or biochemical phenotype.

Analytical sensitivity for sequence variant detection is ~99%.

**Copy Number Analysis:** The sensitivity and specificity of this method for CNV detection is highly dependent on the size of the event, sequence context and depth of coverage for the region involved. The assay is highly sensitive for CNVs of 500 base pairs or larger and those containing at least 3 exons. Smaller (< 500 base pairs) CNVs and those that involving only 1 or 2 exons may or may not be detected depending on the sequence context, size of exon(s) involved and depth of coverage.

### Specimen Requirements

**Type:** DNA, Isolated

**Specimen Requirements:**
- Microtainer

---

Disclaimer: This information is confidential and subject to change without notice. It may not be reproduced in whole or part unless authorized in writing by an authorized EGL representative.
8µg
Isolation using the Perkin Elmer™Chemagen™ Automated Extraction method or Qiagen™Puregene kit for DNA extraction is recommended.

Specimen Collection andShipping:
Refrigerate until time of shipment in 100 ng/µL in TE buffer. Ship sample at room temperature with overnight delivery.

Type: Saliva

Specimen Requirements:
Oragene™Saliva Collection Kit
Oragene™Saliva Collection Kit used according to manufacturer instructions. Please contact EGL for a Saliva Collection Kit for patients that cannot provide a blood sample.

Specimen Collection and Shipping:
Please do not refrigerate or freeze saliva sample. Please store and ship at room temperature.

Type: Whole Blood (EDTA)

Specimen Requirements:
EDTA (Purple Top)
Infants and Young Children (2 years of age to 10 years old): 3-5 ml
Older Children & Adults: 5-10 ml
Autopsy: 2-3 ml unclotted cord or cardiac blood

Specimen Collection and Shipping:
Ship sample at room temperature for receipt at EGL within 72 hours of collection. Do not freeze.

Special Instructions
Please include fundus photographs, electroretinogram (ERG) findings, visual field findings, and visual acuity, if available, for expert review and clinical correlation with test results.

Related Tests
- Eye Disorders: Comprehensive Sequencing and Deletion/Duplication Panels.
- Retinitis Pigmentosa: Deletion/Duplication Panel.